A Study of Olanzapine in Patients With Schizophrenia
Condition: Schizophrenia
MeSH terms: Schizophrenia
Intervention: Rapid-Acting Intramuscular Olanzapine; Placebo
Intervention description: Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections; Administered by means of IM with the possibility of second injection 2 to 4 hours after first injection, for a maximum of 2 injections
Intervention MeSH terms: Olanzapine
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 91.0
Sex: All
Minimum age: 20 Years
Maximum age: 64 Years
Healthy volunteers: No

Summary:

      The primary objectives of the study is to confirm if the efficacy of intramuscular injection
      (IM) olanzapine 10 milligrams (mg) in patients with an exacerbation of schizophrenia with
      acute psychotic agitation is greater than intramuscular placebo by comparing changes from
      baseline to 2 hours after the first IM injection of agitation.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patients who meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition
             Text Revision (DSM-IV-TR) criteria for schizophrenia.

          -  Patients with an exacerbation of schizophrenia with acute psychotic agitation.

          -  Patients who are hospitalized during the study.

          -  Patients, or proxy consenters, understand the nature of the study and sign on an
             informed consent document.

          -  The investigator or sub-investigator(s) judges that the patients are able to cooperate
             with all protocol procedures.

          -  Patients who are considered to be with agitation and appropriate candidates for
             treatment with intramuscular (IM) medication by the investigator or
             sub-investigator(s).

          -  The investigator or sub-investigator(s) believes that it is safe to administer IM
             olanzapine to the patients in consideration of safety, including the anticholinergic
             action of IM olanzapine.

          -  Patients who have a score of 1 or 2 on Agitation-Calmness Evaluation Scale (ACES)
             before the first IM injection of investigational product.

        Exclusion Criteria:

          -  Patients whose Global Assessment of Functioning (GAF) score is less than or equal to
             40 within last 1 year before informed consent.

          -  Patients with defect.

          -  Patients whose agitation continues more than 2 weeks before informed consent.

          -  Patients who were previously treated with antipsychotics and were considered by the
             investigator or sub-investigator(s) to be treatment-resistant to antipsychotics.

          -  Patients who were treated by oral olanzapine at a dose of more than 20 milligrams (mg)
             for more than 4 weeks but did not improve.

          -  Patient who have a history of participation in clozapine trials or treatment with
             clozapine.

          -  Patients who have co-morbidity of mental retardation and personality disorder.

          -  Patients whose agitation is possibly due to brain lesions such as (but not limited to)
             head injury, stroke, brain breeding, and cerebral infection.

          -  Patients with sub-stupor or stupor.

          -  One or more seizures without a clear and resolved etiology. However, if the patient
             has had one or more seizures in the past with an identifiable etiology, and that
             etiology has been resolved, the patient may be entered.

          -  Patients who have a history of DSM-IV-TR substance (except caffeine and nicotine)
             abuse within the past 30 days or substance dependence within the past 6 months before
             informed consent. Or patients who have a history of using illegal drug.

          -  Patients whose agitation is caused by substance abuse or neurologic conditions, in the
             opinion of the investigator or sub-investigator(s).

          -  Patients who have a diagnosis of Parkinson's disease or dementia.

          -  Patients who are actively suicidal (at high risk for suicide attempt) in the opinion
             of the investigator or sub-investigator(s).

          -  Patients with inadequately controlled diabetes, or patients whose treatment for
             diabetes has been changed within 4 weeks before the first IM injection of the
             investigational product. The investigator's discretion will supersede even if the
             patients do not meet the above criteria for concurrent diabetes.

          -  Patients who have received haloperidol decanoate fluphenazine decanoate, or
             fluphenazine enanthate within 8 weeks before the first IM injection of investigational
             product.

          -  Patients who have received risperidone long-acting injection within 12 weeks before
             the first IM injection of investigational product.

          -  Patients who have a history of receiving injectable depot antipsychotics other than
             haloperidol decanoate, fluphenazine decanoate, fluphenazine enanthate and risperidone
             long-acting injection.

          -  Patients who have received antipsychotics or other prohibited concomitant medicines
             within 2 hours before the first IM injection of investigational product.

          -  Patients who have received benzodiazepines within 4 hours before the first IM
             injection of investigational product.